Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
August 30 2017 - 4:00PM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will present at each of the following investor
conferences:
- September 6, 9:05 a.m. ET – Baird 2017
Global Healthcare Conference, New York City
- September 13, 1:35 p.m. ET – Morgan
Stanley 15th Annual Global Healthcare Conference, New York
City
- September 25, 8:00 a.m. ET – Cantor
Fitzgerald Global Healthcare Conference, New York City
A live webcast and replay of each presentation will be
accessible by visiting the “Events and Presentations” section on
the “Investors” page of Enanta’s website at www.enanta.com. The
webcast replay will be available following each presentation and
will be archived for approximately 30 days.
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease inhibitors,
paritaprevir and glecaprevir, discovered and developed through
Enanta’s collaboration with AbbVie, have now been approved by the
FDA as part of AbbVie’s direct-acting antiviral (DAA) regimens,
MAVYRET™ (glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir), for the treatment of
hepatitis C virus (HCV).
Royalties and milestone payments from the AbbVie collaboration
are helping to fund Enanta’s research and development efforts,
which are currently focused on the following disease targets:
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), respiratory syncytial virus (RSV) and hepatitis B virus
(HBV). Please visit www.enanta.com for more information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170830005279/en/
Enanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024